Download PDF
Thromb Haemost 1993; 70(04): 554-561
DOI: 10.1055/s-0038-1649626
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Heparin-Induced Thrombocytopenia (HIT): An Overview of 230 Patients Treated with Orgaran (Org 10172)

H N Magnani
The Medical Research and Development Unit, Organon International BV, Oss, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 02 July 1992

Accepted after revision 19 May 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin-induced thrombocytopenia (HIT) with thrombosis occurs in about 1 in 2,000 heparin-treated patients. The arterial or venous thromboses may threaten life and limb hence alternative anticoagulation is needed. Some alternative treatments are possible i.e. LMWH, Ancrod, prostacyclin analogues, Dextran, aspirin and oral anticoagulants, but each has its drawbacks. This report reviews treatment of HIT patients with Orgaran (Org 10172), a low molecular weight heparinoid.

Because of its proven antithrombotic activity Orgaran was used to treat 230 HIT patients. One hundred and fifty, nine patients presented with at least one thrombotic problem, which in 88 was due to the heparin use. 92.8% of the patients were considered to have adequately responded to Orgaran during the treatment period. Fifty-nine deaths (25.7%) occurred of which 7 (3.0%) were attributed to Orgaran use. The remaining 52 deaths, 27 of which occurred after Orgaran treatment was successfully terminated, were due to the severe underlying disorders in these patients. These results and the lower cross-reactivity rate (≈10%) with the heparin-induced antibody compared with that of the LMWH (>90%) suggest that although problems remain, Orgaran can be a valuable alternative treatment for patients who suffer from HIT and who require anticoagulation.

 

  • References

  • 1 Meuleman DG, Hobbelen P, Van Dedem G, Moelker H. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity. Thromb Res 1982; 27: 353-363
    CrossrefPubMedGoogle Scholar
  • 2 Boneu D, Buchanan MR, Cade JF. et al Effects of heparin and its low molecular weight fractions and other glycosaminoglycans on thrombus growth in-vivo. Thromb Res 1985; 40: 81-89
    CrossrefPubMedGoogle Scholar
  • 3 Ireland H, Lane DA, Flynn A, Anastassiades E, Curtis JR. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemostas 1986; 55: 271-275
    PubMedGoogle Scholar
  • 4 Baruch D, Franssen J, Hemker HC, Lindhout T. Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of AT-III. Thromb Res 1985; 38: 447-458
    CrossrefPubMedGoogle Scholar
  • 5 Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani HN, Dandona P. Comparison of the effects of a conventional heparin and a low molecular weight heparinoid fraction on platelet function. Br J Clin Pharmacol 1984; 17: 43-48
    CrossrefPubMedGoogle Scholar
  • 6 Wester J, Van Mensvoort FWJ, Meuleman DG, Ten CateH, Henny CP, Ten CateJW. Effects of Org 10172, a novel heparinoid on primary haemostasis in rats and humans; a morphological study. Thromb Haemostas 1987; 58: 123
    PubMedGoogle Scholar
  • 7 Henny ChP, Ten CateH. The morphology of human haemostatic plug formation following administration of heparin or the low molecular weight heparinoid Org 10172. Thesis, University of Amsterdam, Amsterdam 1987; 77-94
    PubMedGoogle Scholar
  • 8 Hobbelen PMJ, Vogel GMT, Meuleman DG. Time courses of the antithrombotic effects, the bleeding effects and the interaction with factor Xa and thrombin after administration of the low molecular weight heparinoid, Org 10172, or heparin. Thromb Res 1987; 48: 549-558
    CrossrefPubMedGoogle Scholar
  • 9 Hirsh J. In-vivo effects of low molecular weight heparins on experimental thrombosis and bleeding. Heamostasis 1986; 16: 82-86
    PubMedGoogle Scholar
  • 10 Cade JF, Wood M, Magnani HN, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in the prevention of deep vein thrombosis. Thromb Res 1987; 45: 497-503
    CrossrefPubMedGoogle Scholar
  • 11 Turpie AG, Hirsh J, Jay RM. A double-blind randomised trial of Org 10172, a low molecular weight heparinoid, in the prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; i: 523-526
    PubMedGoogle Scholar
  • 12 Makhoul RG, Greenberg CS, McCann RL. Heparin associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986; 4: 522-528
    CrossrefPubMedGoogle Scholar
  • 13 Chong BH, Ismail F, Cade JF, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-1596
    PubMedGoogle Scholar
  • 14 Böttinger LE. Heparin-induced thromboytopenia. Acta Med Scand 1985; 218: 257-259
    PubMedGoogle Scholar
  • 15 King DE, Kelton J. Heparin-induced thrombocytopenia. Ann Intern Med 1984; 100: 535-540
    CrossrefPubMedGoogle Scholar
  • 16 Towne JB, Bernard VM, Hussey C, Garancis JC. White clot syndrome, peripheral vascular complications of heparin therapy. Arch Surg 1979; 114: 372-377
    CrossrefPubMedGoogle Scholar
  • 17 Rankin JA. Heparin-induced thrombosis (white-clot syndrome) secondary to prophylactic subcutaneous administration of heparin. Can J Surg 1988; 31: 33-34
    PubMedGoogle Scholar
  • 18 Leehey DL, Kanak RJ, Messmore HL, Nawab ZM, Popli S, Ing TS. Heparin-associated thrombocytopenia in maintenance haemodialysis patients. Int J Artificial Organs 1987; 10: 390-392
    PubMedGoogle Scholar
  • 19 Atkinson JLD, Sundt TM, Kazmier FJ, Bowie EJW, Whisnant JP. Heparin-induced thrombocytopenia and thrombosis in acute stroke. Mayo Clin Proc 1988; 63: 353-361
    CrossrefPubMedGoogle Scholar
  • 20 Anonymous. Heparin-induced thrombocytopenia. Australian Adverse Drug Reactions Bulletin. August 1989
    PubMedGoogle Scholar
  • 21 Harenberg J, Zimmerman R. Treatment of heparin-induced thrombocytopenia with thrombosis by a new heparinoid. Lancet 1983; 8331: 986-987
    PubMedGoogle Scholar
  • 22 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemostas 1992; 67: 545-549
    PubMedGoogle Scholar
  • 23 Kiers L, Grigg LE, Cade JF, Street PR, Chong BH. Use of Org 10172 in the treatment of heparin-induced thrombocytopenia and thrombosis. Aust NZ J Med 1986; 16: 719
    CrossrefPubMedGoogle Scholar
  • 24 Henny ChP, Ten CateH, Ten CateJW, Prummel FM, Peters J, Büller HR. Thrombosis prophylaxis in an AT-III deficient pregnant woman: application of the low molecular weight heparinoid Org 10172. Thromb Haemostas 1986; 55: 301-304
    PubMedGoogle Scholar
  • 25 Doherty DC, Ortel TL, De Bruijn N, Greenberg CS, Van Trigt III P. “Heparin-free” cardiopulmonary by-pass: First reported use of heparinoid Org 10172 to provide anticoagulation for cardiopulmonary by-pass. Anesthesiology 1990; 73: 562-565
    CrossrefPubMedGoogle Scholar
  • 26 Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust NZ J Med 1991; 21: 52-54
    CrossrefPubMedGoogle Scholar
  • 27 Ortel TL, Gockerman JP, Califf RM. et al Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemostas 1992; 67: 292-296
    PubMedGoogle Scholar
  • 28 Greinacher A, Drost W, Michels I. et al Heparin associated thrombocytopenia successful therapy with ther heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Haematol 1992; 64: 40-42
    CrossrefPubMedGoogle Scholar
  • 29 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
    PubMedGoogle Scholar
  • 30 Bradbrook I, Magnani HN, Moelker HCT. et al Org 10172: a low molecular weight anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987; 23: 667-675
    CrossrefPubMedGoogle Scholar
  • 31 Stiekema J, Wijnand HP, Van Dinther ThG. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989; 27: 39-48
    CrossrefPubMedGoogle Scholar
  • 32 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
    CrossrefPubMedGoogle Scholar
  • 33 Van Bessien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anti-coagulant and heparin-induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res 1991; 62: 23-29
    CrossrefPubMedGoogle Scholar
  • 34 Peeters LH, Hobbelen PMJ, Verkeste CM. et al Placental transfer of Org 10172, a low molecular weight heparinoid, in the awake late-pregnant guinea-pig. Thromb Res 1986; 44: 277-283
    CrossrefPubMedGoogle Scholar
  • 35 Greinacher A, Michels I, Kiefer V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia (HAT) and selecting a compatible heparin. Thromb Haemostas 1991; 66: 734-736
    PubMedGoogle Scholar
  • 36 Harbrecht NM, Ankrig CJ. Heparin-induced thrombocytopenia type II: platelet aggregation studies with low molecular weight heparins and heparinoid (Org 10172). Thromb Haemostas 1991; 65: 1302
    PubMedGoogle Scholar
  • 37 Kelton J. Heparin-induced thrombocytopenia. Haemostasis 1986; 16: 173-186
    PubMedGoogle Scholar
  • 38 Kyritsis AP, Williams EC, Schutta HS. Cerebral Venous Thrombosis due to Heparin-induced Thrombocytopenia. Stroke 1990; 21: 1503-1505
    CrossrefPubMedGoogle Scholar
  • 39 Prull A, Nechwatal R, Maurer W. Fulminante venöse und arterielle Thrombosen unter Heparintherapie. Dtsch Med Wschr 1990; 115: 456-459
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Henny ChP, Ten CateH, Ten CateJW. et al Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; i: 890-893
    PubMedGoogle Scholar
  • 41 Ten CateH, Henny ChP, Buller HR, Ten CateJW, Magnani HN. Use of heparinoid in haemorrhagic stroke patients with thromboembolic disease. Ann Neurol 1984; 15: 268-270
    CrossrefPubMedGoogle Scholar
  • 42 Biller J, Massey EW, Marler JR. et al A dose escalation study of Org 10172 (low molecular weight heparinoid) in stroke. Neurology 1989; 39: 262-265
    CrossrefPubMedGoogle Scholar
  • 43 Guittard M, Pradalier A, Vincent D, Dry J. Thrombosis of the Right Ventricle and Thrombopenia Induced by Heparin. Presse Med 1988; 17: 871
    PubMedGoogle Scholar
  • 44 Borg JY, Flechet B, Legendre M, Toulemonde F, Piguet H, Moncon-duit M. Severe heparin and pentosan polysulphate-induced thrombocytopenia: clinical aspects in-vitro effects of pentosan polysulphate, low molecular weight (LMW) heparins and oligosaccharides. Thromb Res. 1986 Suppl. VI 96
    PubMedGoogle Scholar
  • 45 Dalger J, Dussarat GV, Dumoulin M. Infarctus myocardique compliquant une thrombopénie induite par le polysulfate de pentosane. Ann Cardiol Angeiol 1988; 37/4: 191-193
    PubMedGoogle Scholar
  • 46 Maiza D, Derlon A, Khayat MC, Coulhon JP, Leporrier M. Rôle du polysulfate de pentosane dans le déclanchement de deux accidents thrombopéniques. Presse Med 1985; 14: 1289-1290
    PubMedGoogle Scholar
  • 47 Follea G, Hamandjian I, Trzeciak MC, Nedey C, Streichenberger R, Dechavanne M. Pentosane polysulfate associated thrombocytopenia. Thromb Res 1986; 42: 413-418
    CrossrefPubMedGoogle Scholar
  • 48 Papazian L, Alazia M, Levy G, François G. Multiple arterial and venous thromboses associated with thrombocytopenia. Rôle of pentosan polysulphate and heparins. Presse Med 1986; 15: 1246-1247
    PubMedGoogle Scholar
  • 49 Blockmans D, Bounameaux H, Vermylen J, Verstraete M. Heparin-induced thrombocytopenia, platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities. Thromb Haemostas 1986; 55: 90-93
    PubMedGoogle Scholar
  • 50 Gouault-Heilmann M, Huet Y, Adnot S. et al Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis 1987; 17: 134-140
    PubMedGoogle Scholar
  • 51 Copplestone A, Oscier DG. Heparin-induced thrombocytopenia in pregnancy. Br J Haematol 1987; 65: 248
    PubMedGoogle Scholar
  • 52 Brace LD, Fareed J. Heparin-induced platelet aggregation: Dose response relationships for a low molecular weight derivative (PK 10169) and its subfractions. Thromb Res 1986; 42: 769-782
    CrossrefPubMedGoogle Scholar
  • 53 Le Querrec A, Derlon A, Tobelem G, Thomas M. Pentosane polysulphate like heparin may induce severe thrombocytopenia. Thromb Res. 1986 Suppl. VI 90
    PubMedGoogle Scholar
  • 54 Paille F, Boccaccini A, DeKorwin JD. et al Thrombopénie sous héparine de bas poids moléculaire aprè traitement par pentosane polysulphate. Therapie 1988; 43: 322-323
    PubMedGoogle Scholar
  • 55 Roussi JH, Houbouyan LL, Goguel AF. Use of low molecular weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; ii: 1183
    PubMedGoogle Scholar
  • 56 Horellou MH, Conard J, Lecrubier C. et al Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemostas 1984; 51: 134
    PubMedGoogle Scholar
  • 57 Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemostas 1986; 55: 37-39
    PubMedGoogle Scholar
  • 58 Troussard X, Mosquet B, Bigot MC, Derlon A, Khayat MC, Moulin MA. Thrombopénie sous héparine. Therapie 1986; 41: 69-72
    PubMedGoogle Scholar
  • 59 Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary by-pass with a low molecular weight heparin fraction. Lancet 1983; ii: 1374
    PubMedGoogle Scholar
  • 60 Faivre R, Kieffer Y, Bassand JP, Maurat JP. Les thrombopénies graves à l’héparine: Intérêt de l’utilisation de l’héparine à bas poids moleculaire. Arch Mal Coeur 1985; 78: 27-30
    PubMedGoogle Scholar
  • 61 Huisse MG, Huet Y, Zygelman M, Guillin MC. Une tentative thérapeutique dans une cas de thrombopénie enduite par l’héparine. Nouv Rev Fr Haematol 1983; 25: 139
    PubMedGoogle Scholar
  • 62 Roussi J, Houbouyan L, Rosenthal D, Toulemonde F, Goguel A. Success du traitement par une fraction d’héparin de bas poids moléculaire dans un cas d’embolie pulmonaire compliquant une thrombopénie induite par l’héparine. Nouv Rev Fr Haematol 1983; 25: 273-274
    PubMedGoogle Scholar
  • 63 Gruel Y, Guerois C, Delahousse B. et al Traitement des thrombopénies et thromboses sous héparins Standard: Résultats obtenus par l’utilisation de fractions des bas poids moléculaire (26 cas). Nouv Rev Fr Haematol 1984; 26: 135
    PubMedGoogle Scholar
  • 64 Grau E, Fontucuberta J, Martinez R, Latorre J, Felez J, Rutllant MC. Thrombopénie sévère précoce induite par l’héparine non-fractionée: Tentative thérapeutique par une héparine de bas poids moléculaire. Nouv Rev Fr Haematol 1985; 27: 385-387
    PubMedGoogle Scholar
  • 65 Gruel Y, Lerou J, Guerois C. et al Thrombopénie et thrombose sous héparine. Necessité des tests d’aggregation ayant le traitement par l’héparine de bas poids moleculaire. La presse Médicale 1985; 14: 166
    PubMedGoogle Scholar
  • 66 Huisse MG, Guillin MC, Bezeaud A, Toulemonde F, Kitzis M, Andreassian B. Heparin-associated thrombocytopenia. In-vitro effects of different low molecular weight heparin fractions. Thromb Res 1982; 27: 485
    CrossrefPubMedGoogle Scholar
  • 67 Cornu P, Scalet M, Sternberg CI, Racine S. Thrombopénies induites par l’héparine (TIH): Etude in vitro des héparines de bas poids moleculaires (HBPM) et du polysulfate de pentosane (PSP-Hemoclar). Nouv Rev Fr Haematol 1984; 26: 135
    PubMedGoogle Scholar
  • 68 Horrellou MH, Conard J. Lecrubier. et al Thrombopénie induite par l’héparine, entretenue par l’héparine de bas poids moleculaire. Nouv Rev Fr Haematol 1984; 26: 134
    PubMedGoogle Scholar
  • 69 Sardin B, Gouille D, Desport JC. et al Thrombopénies immunoallergiques induites par l’héparine: Diagnostic, traitement et prévention. J Chir (Paris) 1987; 124: 349-350
    PubMedGoogle Scholar
  • 70 Bollaert PE, Laprevoté-Heully MC, Mourizi M, Lambert H, Larcan A. Thrombopénie grave associée au traitement par polysulfate de pentosane. Ann Fr Anesth Réanim 1986; 5: 539-541
    CrossrefPubMedGoogle Scholar
  • 71 Leroy J, Leclerc MH, Delahousse B. et al Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemostas 1985; 11: 326-329
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Gouault-Heilmann M, Payen D, Contant G, Intrator L, Huet Y, Schaeffer A. Thrombocytopenia related to synthetic heparin an analogue therapy. Thromb Haemostas 1985; 54: 557
    PubMedGoogle Scholar
  • 73 Gouault-Heilmann M, Contant G, Intrator L, Brun-Ney D, Huet Y. Thrombopénie à l’heparin, circulation extra-corporelle et héparine de bas poids moleculaire. Nouv Rev Fr Haematol 1984; 26: 134
    PubMedGoogle Scholar
  • 74 Delagardelle C, Harf C, Dondelinger RF. et al Traitement par thrombolyse locale d’une thrombose artérielle massive par thrombopénie induite par l’heparine. Arch Mal Coeur 1990; 83: 113-115
    PubMedGoogle Scholar
  • 75 Leclercq C, De Place C, Rioux C, Mabo P, Paillard F, Daubert JC. Infarctus du myocarde et thrombose biventriculaire massive au cours d’une thrombopénie induite par le pentosan polysulfate et l’héparine. Arch Mal Coeur 1990; 83: 117-120
    PubMedGoogle Scholar
  • 76 Tardy B, Page Y, Tardy-Poncet B, Comtet C, Zeni F, Bertrand JC. Thrombopénie induite par une héparine de bas poids moleculaire. Therapie 1990; 45: 453
    PubMedGoogle Scholar
  • 77 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Progr Haemostas Thromb 1991; 10: 1-34
    PubMedGoogle Scholar